Edgewise Therapeutics Inc (NAS:EWTX)
$ 28.74 -0.92 (-3.1%) Market Cap: 2.72 Bil Enterprise Value: 2.32 Bil PE Ratio: 0 PB Ratio: 5.55 GF Score: 35/100

Edgewise Therapeutics Inc at Stifel CNS Days (Virtual) Transcript

Mar 28, 2023 / 06:00PM GMT
Release Date Price: $7 (+0.86%)
Paul Matteis
Stifel, Nicolaus & Co., Inc. - Analyst

Great. Good afternoon, everybody. It's my pleasure to be hosting the Edgewise Therapeutics team. With me is Kevin and Behrad. They're going to give an overview of the company for about 15 minutes or so, and then we can do Q&A. (Conference Instructions)

So Kevin, I can turn it over to you, and thank you again for taking the time to join us. Appreciate it.

Kevin Koch
Edgewise Therapeutics, Inc. - President & CEO

Great, Paul. Thank you very much. This is Edgewise Therapeutics. I'm Kevin Koch, the CEO. This is my disclaimer for what I'll be telling you today.

So Edgewise. Experienced management team with deep expertise in muscle physiology and biology targeting rare muscle disorders. We work almost entirely on novel targets to optimize our ability to provide benefit to the patients and differentiated benefit to the patients. We believe our first program 5506 can become a foundational therapy for multiple muscular dystrophies because of the ability to work across mutations in this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot